Valproic acid amide in the treatment of affective and schizoaffective disorders.
During 26-51 months of valproic acid amide treatment of 15 patients with affective and schizoaffective disorders, the authors observed reduction in the number, length and severity of affective episodes, especially mania. In a few patients, "fragmentation" of long and severe relapses into short and mild mania or depression occurred. The number and length of hospital admissions dropped in all patients.
D000328:Adult; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology; D014150:Antipsychotic Agents / Q000494:pharmacology; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000517:prevention & control; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D006801:Humans; D008875:Middle Aged; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000517:prevention & control; D012008:Recurrence; D012917:Social Adjustment; D014635:Valproic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000929:Antidepressive Agents, Tricyclic; D014150:Antipsychotic Agents; D014635:Valproic Acid; C004651:dipropylacetamide